The ultimate goal of the proposal presented herein is to use E. coli as whole cell biocatalysts for the production of a wide variety of TDP-deoxysugars including di- and tri-deoxysugars, amino sugars and branched-chain sugars. These specialized activated hexoses are found as important structural components throughout plant and microbial secondary metabolites often playing a crucial role in conferring activity in bioactive natural products such as antibiotics and anticancer therapeutics. In Phase I, we proposed to investigate a novel approach to produce rare TDP-deoxysugars in Escherichia coli through metabolic engineering. During the Phase I study we successfully modified E. coli AB707 to accumulate TDP-4-keto-6-deoxy-D-glucose (TKDG;a key intermediate of TDP-deoxysugars) through inactivations and overexpression of specific pathway enzymes. Using exogenous TDP-deoxysugar biosynthetic enzymes, the accumulated TKDG pools were converted to specific TDP-deoxysugars in yields up to 80 mg/L, exceeding our Phase I goal. The success of the feasibility study will be expanded in Phase II. Specifically, we will further increase TDP- deoxysugar yields through additional genetic engineering experiments to limit loss of glucose- -phosphate to competing pathways, increase thymidine triphosphates (TTP) pools, reduce catabolite repression by glucose, and optimize fermentation conditions. We will also expand our range of TDP-deoxysugar products by cloning and expressing several exogenous sugar biosynthetic genes for the production of 0 additional complex TDP-deoxysugars. In Phase III we will commercialize the technology by carrying out Partnered R&D programs with strategic partners to make new glycoconjugates, by offering TDP-deoxysugars as well as deoxysugars as research reagents, and by licensing the technology on an application-specific basis.

Public Health Relevance

This project is aimed toward developing E. coli as a whole-cell biocatalyst for the production of activated TDP-deoxysugars. These deoxysugars can be used to make derivatives of natural products with new therapeutic properties, for example, antibiotics that are effective against antibiotic-resistant bacteria.

National Institute of Health (NIH)
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Marino, Pamela
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Zuchem, Inc.
United States
Zip Code